p*e
2 楼
I am not sure...
j*2
3 楼
好，听你的。
【在 p**********e 的大作中提到】
: I am not sure...
【在 p**********e 的大作中提到】
: I am not sure...
p*e
4 楼
周末刚刚被某娱乐周刊评为2014的潜力股
2014 Top health-care stock No. 1: Joining the pack
It's a heck of a lot easier to determine the potential value a biotech when
there's a company further ahead with nearly identical assets. Orexigen (
NASDAQ: OREX ) has two.
The biotech is developing an obesity drug Contrave, which will be reviewed
by the FDA in 2014. Further ahead, Arena Pharmaceuticals (NASDAQ: ARNA )
developed obesity drug Belviq that launched this year. VIVUS (NASDAQ: VVUS
) sells Qsymia, which has been on the market for a little over a year.
Without an approval in hand, investors are rightfully discounting Orexigen.
Or put another way, Orexigen should have a similar value to Arena
Pharmaceuticals and VIVUS once investors are convinced that it has the same
potential as the other two.
An approval of Contrave looks highly likely after Orexigen successfully
completed all the FDA's requests from an earlier rejection. Orexigen has the
potential to double in value next year, which could make it one of 2014's
top health-care stocks.
【在 j********2 的大作中提到】
: RT
2014 Top health-care stock No. 1: Joining the pack
It's a heck of a lot easier to determine the potential value a biotech when
there's a company further ahead with nearly identical assets. Orexigen (
NASDAQ: OREX ) has two.
The biotech is developing an obesity drug Contrave, which will be reviewed
by the FDA in 2014. Further ahead, Arena Pharmaceuticals (NASDAQ: ARNA )
developed obesity drug Belviq that launched this year. VIVUS (NASDAQ: VVUS
) sells Qsymia, which has been on the market for a little over a year.
Without an approval in hand, investors are rightfully discounting Orexigen.
Or put another way, Orexigen should have a similar value to Arena
Pharmaceuticals and VIVUS once investors are convinced that it has the same
potential as the other two.
An approval of Contrave looks highly likely after Orexigen successfully
completed all the FDA's requests from an earlier rejection. Orexigen has the
potential to double in value next year, which could make it one of 2014's
top health-care stocks.
【在 j********2 的大作中提到】
: RT
c*o
5 楼
青龙老师说点评下。
t*l
6 楼
就是一阿斗不如allin $STXS
【在 c*******o 的大作中提到】
: 青龙老师说点评下。
【在 c*******o 的大作中提到】
: 青龙老师说点评下。
相关阅读
cao scty京东死死地钉在20上不动了。大盘新高了优酷要收绿了？比赛里高手如云如何买mutual fund忘记了哪位大牛说过的呢，赢了伪币输了账户！大牛就是大牛，不是我们这些青蛙能比的。老李这样的水平，真想得大赛冠军[通知] Stock 举办博彩：5/27 SP500 涨跌公布一下股版大牛老李股版值班的日子你都没赚看了YAHOO 留言板优酷上的操作彻底看出了教授和老李的差别power by three horses: AAPL, AMZN, GOOG机会有时终须有，机会无时莫强求5000股yoku，赚了1万关于cloud与big data板块的近期财报及下周走势BB收紧了， 是不是意味着要井喷了？ICPT下周爆发